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ABSTRACT
Background: Fluticasone furoate nasal spray (FFNS) is a glucocorticoid developed for the treatment of aller-
gic rhinitis (AR). This is the first randomized clinical trial to assess the efficacy and safety of FFNS in Japanese
children with perennial AR (PAR).
Methods: In this multicentre, randomized, double-blind, placebo-controlled, parallel-group, phase III study,
261 children aged 6 to <15 years were treated with FFNS 55 μg, once daily or placebo for two weeks. Nasal
and ocular symptoms were rated by parentsguardianspatients in the patient daily diary. The primary endpoint
was the mean change from baseline in the three total nasal symptom score (3TNSS). In addition, rhinoscopic
findings were rated by the investigators as an efficacy measure. As a safety measure, adverse events and clini-
cal chemistry and hematology were evaluated.
Results: Mean change from baseline over the entire treatment period in 3TNSS was greater in the FFNS 55
μg group compared with placebo, and the difference was statistically significant (p < 0.001). Significant im-
provements in rhinoscopic findings of swelling of inferior turbinate mucosa and quantity of nasal discharge were
also observed. The total ocular symptom score (TOSS) was reduced significantly in the FFNS 55 μg group,
compared with placebo, in the second week in a subgroup of patients with baseline TOSS > 0. The incidence of
adverse events was similar between FFNS 55 μg (18%) and placebo (19%).
Conclusions: Two-week treatment with FFNS 55 μg, once daily is effective and tolerable in Japanese chil-
dren aged 6 to <15 years with PAR.
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INTRODUCTION
Allergic rhinitis (AR) is a highly prevalent chronic
disease, affecting approximately 30% of the children
in Japan.1,2 The prevalence varies worldwide and is
increasing in most countries.3,4 AR is characterized
by the three major symptoms of paroxysmal and re-
current sneezing, watery rhinorrhea, and nasal con-
gestion.1,2 In the Practical Guideline for the Manage-
ment of Allergic Rhinitis in Japan, AR has been classi-
fied as perennial AR (PAR) or seasonal AR (SAR) de-
pending on the timing and duration of symptoms.1,2
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Common allergens for PAR include dust mites, ani-
mal dander, molds and cockroaches, and allergens
for SAR include Japanese cedar pollens, ragweed and
orchard grass.5,6 Severity of AR is classified as mild,
moderate, severe (and most severe) using a unique
scoring system based on frequency of symptoms in a
day, including episodes of paroxysmal sneezing and
episodes of nose blowing.1,2 This scoring system was
used as an efficacy measure in this study.
AR in children has a significant impact on the qual-
ity of life (QOL), sleep and school productivity.7-9 The
performance of children with AR at school can be im-
paired by cognitive dysfunction related to the AR.10 In
addition, if left untreated, comorbid conditions associ-
ated with AR, including asthma and otitis media, can
be problematic in children.11,12 Moreover, AR is re-
ported to be associated with a significant economic
burden.3,13,14
AR is often associated with ocular symptoms.3
Some patients consider ocular symptoms to be more
annoying than nasal symptoms, and some studies
have shown that ocular symptoms also impair pa-
tients’ QOL.15-17
Corticosteroids constitute a well established anti-
inflammatory therapy that effectively controls the na-
sal symptoms of AR, and international guidelines rec-
ommend intranasal corticosteroids (INS) as first-line
therapy for patients with moderate-to-severe or per-
sistent disease.3 In the Japanese guideline, INS are
recommended as the most effective medications to
improve symptoms of AR.1,2 INS have a broad spec-
trum of efficacy for a range of nasal symptoms, in-
cluding congestion, rhinorrhea and sneezing.1-3 In ad-
dition, INS have been reported to improve eye symp-
toms that accompany AR.18-21
Fluticasone furoate nasal spray (FFNS) is a gluco-
corticoid developed for the treatment of AR, and is
administered in a unique, side-actuated device.22,23
This delivery system was designed for ease of self-
administration, as well as for convenient parent
caregiver administration to children.24 As a treatment
for AR, FFNS is currently approved in more than 100
countries and used both in adults and children in
many countries including Europe and America. Al-
though well studied in healthy volunteers and adult
patients with AR and approved for the use in adults,
the clinical efficacy and safety of FFNS has not been
investigated in children with AR in Asia including Ja-
pan. In Japanese children, few studies evaluated effi-
cacy and safety of INS in double-blind design. In addi-
tion, to our knowledge, no study has evaluated the ef-
ficacy of FFNS on ocular symptoms associated with
PAR in children.
We conducted two clinical studies to evaluate the
efficacy and safety of FFNS 55 μg in Japanese chil-
dren. One study was a twelve-week, open study to as-
sess the safety, efficacy and systemic exposure of
once-daily FFNS 55 μg in Japanese children aged 2 to
<15 years with PAR, which is reported elsewhere.
(ClinicalTrials.gov Identifier: NCT01622231, GlaxoS-
mithKline protocol number: FFR116365.) The other
study was a two-week, randomized, phase III study to
assess the efficacy on nasal and ocular symptoms,
and safety of once-daily FFNS 55 μg compared with
placebo in Japanese children aged 6 to <15 years with
PAR, which we report in this article.
METHODS
This multicenter, randomized, double-blind, placebo-
controlled, parallel-group, phase III study was con-
ducted at 22 centers in Japan.
Eligible patients entered a one to two-week screen-
ing period. Patients meeting the randomization crite-
ria were randomly assigned to one of the two treat-
ment groups, FFNS 55 μg or placebo, in a 1 : 1 ratio.
The vehicle placebo contained the following: purified
water, glucose anhydrous, microcrystalline cellulose
and carboxymethylcellulose sodium, polysorbate 80,
benzalkonium chloride, and edentate disodium. Pa-
tients were treated once daily in the morning for two
weeks and had a clinic visit every week. A follow up
visitphone call was scheduled one week after the
end of the treatment to confirm the safety. Patients
who completed all of the visits including the follow up
are deemed to have completed the study.
PATIENTS
Eligible patients were aged 6 to <15 years with a his-
tory of PAR for one year or more, and positive for
both a specific immunoglobulin E (IgE) antibody test
to a PAR allergen (house dust mite or house dust)
and nasal eosinophil counts, and with the three total
nasal symptom score (3TNSS) of 4 to <8 at baseline.
Patients were excluded from the study if they had
SAR symptoms attributable to pollen which would be
present in their geographic area during study partici-
pation, had an co-morbid disorder which might affect
the result of the study (e.g. acutechronic sinusitis,
nasal polyps, upper respiratory or eye infection), or
had a co-morbid disease where inclusion in the study
would have been inappropriate based on safety con-
cerns (e.g. tuberculosis, infection without effective
antibacterials, serious hepaticrenalcardiacpulmo-
nary dysfunction or a hematopoietic disorder, uncon-
trolled hypertensiondiabetes mellitus, or asthma
[except for mild intermittent cases]). Patients were
also excluded if they had used medications which
might affect the efficacy assessment of the study (e.g.
systemic corticosteroids within eight weeks of study
initiation).
Use of any treatment for allergic rhinitis, excluding
the study medication, and any concomitant medica-
tion which might affect the efficacy assessments of
the study (e.g. corticosteroids) were prohibited dur-
ing the screening and treatment periods.
FFNS in Japanese Children with PAR
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EFFICACY ASSESSMENTS
The primary efficacy endpoint was the mean change
from baseline in 3TNSS over the entire treatment pe-
riod. The 3TNSS is a common endpoint used for as-
sessment in clinical studies of allergic rhinitis in Ja-
pan. Parentsguardianspatients were instructed to
record patients’ symptom scores (individual nasal and
ocular symptoms and troubles with daily life) in the
patient diary every day during the screening and
treatment periods. The baseline values were the aver-
age score during the four consecutive days prior to
randomization. Secondary efficacy values include 3
TNSS, the four total nasal symptom score (4TNSS),
the total ocular symptom score (TOSS), individual na-
sal and ocular symptom scores, score for troubles
with daily life, the rhinoscopic findings score, and
overall evaluation of the response to therapy. Investi-
gators scored rhinoscopic findings at baseline (ran-
domization) and at each visit during the treatment pe-
riod. Parentsguardianspatients and investigators
scored overall evaluation of the response to therapy
at the end of the treatment period.
The 3TNSS is the sum of individual four-point
scores for sneezing (number of episodes of paroxys-
mal sneezing in a day; 11 times: 3, 10-6 times: 2, 5-1
times: 1, none: 0), rhinorrhea (number of episodes of
nose blowing in a day; 11 times: 3, 10-6 times: 2, 5-1
times: 1, none: 0), and nasal congestion (a severe na-
sal congestion causing prolonged oral breathing in a
day: 3, severe nasal congestion causing occasional
oral breathing in a day: 2, nasal congestion without
oral breathing: 1, none: 0). The 4TNSS is the sum of
individual four-point scores for sneezing, rhinorrhea,
nasal congestion, and nasal itching (severe symptom
that causes interference with activities of daily living:
3, definite awareness of symptom that is tolerable [in-
termediate between 3 and 1]: 2, minimal awareness of
symptom: 1, none: 0). TOSS is the sum of individual
four-point scores for eye itching, tearing and eye red-
ness, all of which are assessed as follows: severe
symptom that causes interference with activities of
daily living: 3, definite awareness of symptom that is
tolerable (intermediate between 3 and 1): 2, minimal
awareness of symptom: 1, none: 0. Score for troubles
with daily life is a four-point score assessed as: painful
and complicating daily life: 3, intermediate between 3
and 1: 2, few troubles with daily life: 1, no troubles: 0.
Rhinoscopic findings were assessed based on four-
point scores of swelling of inferior turbinate mucosa
(impossible to see middle turbinate: 3, intermediate
between 3 and 1: 2, possible to see center of the mid-
dle turbinate: 1, none: 0) and quantity of nasal dis-
charge (filled: 3, intermediate between 3 and 1: 2,
small amount adhered: 1, none: 0). Overall evaluation
of response to therapy was assessed using seven-
point scores: significantly improved: 0, no change: 4,
significantly worse: 7. The individual nasal symptoms
of sneezing, rhinorrhea, nasal congestion, and rhino-
scopic findings are based on the Japanese guide-
line.1,2
SAFETY ASSESSMENTS
Safety of FFNS was assessed by frequency and sever-
ity of adverse events and laboratory tests (clinical
chemistry and hematology). Adverse events were
monitored during the treatment and follow up period.
Treatment compliance was assessed through patient
diary card recording.
STATISTICAL ANALYSES
To verify the superiority of FFNS 55 μg over placebo
as the primary endpoint, a sample size of 250 patients
(125 patients per group) was required to provide sta-
tistical power of 90% at a two-tailed level of signifi-
cance of 5%, assuming a treatment difference of 0.7
and a standard deviation of 1.7, based on our previous
study.25 In order to have 250 evaluable patients, it was
planned to randomize 260 patients.
Efficacy analyses were performed for the full analy-
sis set (FAS) of patients who were randomized to a
treatment, received at least one dose of the study
medication and completed at least one diary assess-
ment of 3TNSS after dosing with the study medica-
tion. The primary analysis was a two-sided compari-
son of the two treatment groups, FFNS 55 μg and pla-
cebo, using analysis of covariance (ANCOVA) with
adjustments for baseline value, age and gender. For
the secondary efficacy endpoints of rhinoscopic find-
ings (swelling of inferior turbinate mucosa and quan-
tity of nasal discharge) and overall evaluation of re-
sponse to therapy, differences between the two treat-
ment groups were assessed by pairwise comparison,
using the Wilcoxon two-sample test. For the other
secondary efficacy endpoints, differences between
the two treatment groups were assessed in the same
way as the primary analysis.
Safety analyses were performed for the safety
population (SP) of patients who received at least one
dose of the study medication.
ETHICAL APPROVAL AND CLINICAL TRIAL
REGISTRATION
The study was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice
guidelines. Institutional review boards at each center
approved the protocol of this study. Written informed
consent was obtained from a parent or a guardian of
each child participating in the study. Assent was
taken from all children aged twelve years and older.
All children under twelve years were informed de-
pending on their understanding, and assent was
taken if appropriate. The ClinicalTrials.gov Identifier
is NCT01630135. The GlaxoSmithKline protocol
number is FFR116364.
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Table　1　Subject demographics (FAS)
Placebo (N = 130) FFNS 55 μg (N = 131) Total (N = 261)
Age (years)
Mean ± SD 10.1 ± 2.22 10.0 ± 2.32 10.1 ± 2.26
Min-Max 6-14 6-14 6-14
Gender, n (%)
Male 79 (61%) 85 (65%) 164 (63%)
Female 51 (39%) 46 (35%)  97 (37%)
Duration of PAR, n (%)
<2 years 16 (12%) 14 (11%)  30 (11%)
≥2 to <5 years 49 (38%) 49 (37%)  98 (38%)
≥5 years 65 (50%) 68 (52%) 133 (51%)
FAS, full analysis set; FFNS, fl uticasone furoate nasal spray; PAR, perennial allergic rhinitis.
Table　2　Mean change from baseline in 3TNSS (FAS)
Placebo (N = 130) FFNS 55 μg (N = 131)
Baseline Mean (SD) 5.2 (1.06) 5.0 (0.94)
Entire treatment period LS mean change (SE) -0.89 (0.12) -1.98 (0.12)
LS mean difference† - -1.089
p-value vs. placebo - <0.001
Week 1 LS mean change (SE) -0.70 (0.12) -1.60 (0.12)
LS mean difference† - -0.894
p-value vs. placebo - <0.001
Week 2 LS mean change (SE) -1.10 (0.13)‡ -2.38 (0.13)
LS mean difference† - -1.279
p-value vs. placebo - <0.001
3TNSS, three total nasal symptom score; FAS, full analysis set; FFNS, fl uticasone furoate nasal spray; LS, least square.
†LS mean difference = LS mean change in FFNS 55 μg minus LS mean change in placebo.
‡n = 128.
RESULTS
STUDY POPULATION
Of the 307 patients screened in the study, 261 pa-
tients were randomized to one of the two treatment
groups; 131 patients in the FFNS 55 μg group and
130 patients in the placebo group. All of the 261 pa-
tients were included in the analysis of efficacy and
safety (FAS and SP). Of the 261 patients randomized,
259 patients (>99%) completed the study and two pa-
tients in the placebo group were withdrawn from the
study due to a protocol deviation based on the exclu-
sion criterion, but included in the analysis.
The demographic and baseline characteristics for
the FAS population were similar between the two
treatment groups and are summarized in Table 1. All
patients were of Japanese ethnicity. Average age was
10.1 years in the placebo group and 10.0 years in the
FFNS 55 μg group. Duration of PAR was at least two
years in 89% of patients. All patients were positive for
one of the PAR allergens (house dust mite or house
dust constituted an inclusion criterion) and positive in
nasal eosinophil counts. The percentage of patients
with a positive IgE test for each allergens was high
(98-100%) and similar in the two treatment groups.
Mean baseline 3TNSS was approximately 5 (placebo:
5.2, FFNS 55 μg: 5.0) for the two treatment groups,
indicating that the study population consisted mainly
of moderate cases. The mean rate of treatment com-
pliance was also similar among the two treatment
groups (placebo: 99.34%, FFNS 55 μg: 99.03%).
EFFICACY
Primary efficacy analyses were performed in the FAS
population of 261 patients aged 6 to <15 years. FFNS
55 μg significantly improved nasal symptoms; the
least square (LS) mean change from baseline over
the entire treatment period in 3TNSS was greater for
FFNS 55 μg (-1.98) than for placebo (-0.89), and the
difference (-1.089) was statistically significant (p <
0.001, Table 2). FFNS 55 μg also showed significantly
greater improvements compared with placebo with
respect to the LS mean change from baseline in 3
TNSS in Weeks 1 and 2 (Table 2). The mean change
from the baseline in 3TNSS over the two weeks of the
treatment period is presented in Figure 1. A signifi-
cant treatment difference in mean change from base-
line for 3TNSS was first observed on day 2 (p < 0.001)
FFNS in Japanese Children with PAR
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Fig.　1　Mean change from baseline in 3TNSS (FAS). *p < 0.001. Pairwise (two-
sided) comparison using an analysis of covariance (ANCOVA) (FFNS 55 μg vs. 
Placebo). No adjustments for multiplicity. 3TNSS, three total nasal symptom 
score; FFNS, fl uticasone furoate nasal spray; LS, least square; FAS, full analysis 
set.
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for FFNS 55 μg compared with placebo and was
maintained throughout the treatment period. FFNS
55 μg significantly improved all four individual nasal
symptoms assessed and the 4TNSS compared with
placebo in terms of the LS mean change from base-
line in Weeks 1, 2 and over the entire treatment pe-
riod (Table 3).
Significant improvements in rhinoscopic findings,
swelling of inferior turbinate mucosa (Fig. 2A) and
quantity of nasal discharge (Fig. 2B) were observed
in FFNS 55 μg compared with placebo. For the rhino-
scopy score of swelling of inferior turbinate mucosa,
the proportion of patients rated ‘3’ (impossible to see
middle turbinate) decreased with FFNS 55 μg: 39% at
baseline, 18% at week 1, 10% at week 2early with-
drawal (EW). For the rhinoscopy score of quantity of
nasal discharge, the proportion of patients rated ‘0’
(None) increased with FFNS 55 μg; 6% at baseline,
29% at week 1, 48% at week 2EW.
Efficacy analyses of ocular symptoms were per-
formed in a subgroup of patients with a baseline
TOSS > 0 (191 patients). Mean baseline TOSS was ap-
proximately 2 (placebo: 2.3, FFNS 55 μg: 2.1) for the
two treatment groups, indicating that the study popu-
lation consisted mainly of cases with mild ocular
symptoms. TOSS was reduced significantly in FFNS
55 μg compared with placebo in the second week and
reduced numerically but not significantly in the first
week (Table 4).
QOL assessment was performed using the score
for troubles with daily life. A significantly greater de-
crease in the mean change from baseline over the en-
tire treatment period with respect to the score for
troubles with daily life was observed in FFNS 55 μg
compared with placebo (LS mean difference: -0.302,
95%CI: -0.42, -0.19, p < 0.001).
Treatment differences, determined by overall re-
sponse to therapy were significant for FFNS 55 μg
compared with placebo (p < 0.001) both in parent
guardianpatient assessment and investigator assess-
ment. A greater percentage of patients receiving
FFNS 55 μg (parentguardianpatient: 21%, investiga-
tor: 24%) rated the overall response to therapy as “sig-
nificantly improved” compared with patients receiv-
ing placebo (parentguardianpatient: 2%, investiga-
tor: 9%).
SAFETY AND TOLERABILITY
Safety and tolerability analyses were conducted in the
SP, comprising 261 patients aged 6 to <15 years.
Treatment with FFNS 55 μg was well tolerated over
the two-week treatment period. Adverse events re-
ported during the study were of mild or moderate in-
tensity and of similar type and frequency across the
two treatment groups. The proportion of patients with
at least one adverse event was similar across the
groups (placebo: 19%, FFNS 55 μg: 18%). The most
frequently reported adverse events observed in this
study were nasopharyngitis and epistaxis (Table 5).
There were no serious adverse events and no deaths.
No patients withdrew as a result of drug-related or
drug-unrelated adverse events. Drug-related adverse
events was reported by six (4%) patients in the pla-
cebo group and by one (<1%) patient in FFNS 55 μg
group. The drug-related adverse event reported with
FFNS 55 μg was a case of nasal discomfort. Clinical
Okubo K et al.
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Table　3　Mean change from baseline in 4TNSS and each individual symptom score over the entire treatment period (FAS)
Placebo (N = 130) FFNS 55 μg (N = 131)
4TNSS
Baseline Mean (SD) 6.1 (1.58) 6.0 (1.34)
Entire treatment period LS mean change (SE) -1.01 (0.15) -2.4 (0.15)
LS mean difference† - -1.393
p-value vs. placebo - <0.001
Rhinorrhea
Baseline Mean (SD) 1.9 (0.60) 1.8 (0.56)
Entire treatment period LS mean change (SE) -0.31 (0.05) -0.69 (0.05)
LS mean difference† - -0.383
p-value vs. placebo - <0.001
Nasal congestion
Baseline Mean (SD) 1.7 (0.62) 1.5 (0.66)
Entire treatment period LS mean change (SE) -0.36 (0.05) -0.70 (0.05)
LS mean difference† - -0.339
p-value vs. placebo - <0.001
Sneezing
Baseline Mean (SD) 1.6 (0.61) 1.7 (0.60)
Entire treatment period LS mean change (SE) -0.21 (0.04) -0.60 (0.04)
LS mean difference† - -0.391
p-value vs. placebo - <0.001
Nasal itching
Baseline Mean (SD) 1.0 (0.76) 1.0 (0.72)
Entire treatment period LS mean change (SE) -0.12 (0.04) -0.41 (0.04)
LS mean difference† - -0.292
p-value vs. placebo - <0.001
4TNSS, three total nasal symptom score; FAS, full analysis set; FFNS, fl uticasone furoate nasal spray; LS, least square.
†LS mean difference = LS mean change in FFNS 55 μg minus LS mean change in placebo.
chemistry and hematology results did not show any
findings of clinical concern.
DISCUSSION
This is the first randomized clinical study of FFNS in
Japanese children, first study in Asian children as
well. The objective of this study was to evaluate effi-
cacy and safety of FFNS 55 μg, given once daily over
a period of two weeks, compared with placebo, in
Japanese children aged 6 to <15 years with PAR.
The primary endpoint in this study is 3TNSS,
which is a common primary endpoint in Japan. With
regard to the mean change from baseline in 3TNSS
over the entire treatment period, the change in 3
TNSS was significantly greater in the FFNS 55 μg,
once daily group compared with placebo. INS has
been shown to be effective for all three of the typical
nasal symptoms, sneezing, rhinorrhea and nasal con-
gestion, and is recommended for both types, sneez-
ing and rhinorrhea type, and nasal blockagecom-
bined type in the Japanese guideline.1,2 The results of
this study show that FFNS 55 μg significantly im-
proved all of the individual nasal symptoms assessed:
sneezing, rhinorrhea, nasal congestion and nasal itch-
ing, compared with placebo. Findings in nasal symp-
toms in this study add important information to the
evidence for the efficacy of INS in Japanese children
with AR, as few placebo-controlled studies have been
conducted in Japanese children.
4TNSS, which is a common primary endpoint in
global studies, was also evaluated in this study. The
mean change in 4TNSS from baseline was signifi-
cantly greater in the FFNS 55 μg group compared
with placebo. Máspero et al. reported that FFNS 55
μg showed significantly greater reduction in rTNSS,
the sum of four individual symptom scores for rhinor-
rhea, nasal congestion, nasal itching, and sneezing
scored in a reflective manner, in non-Japanese chil-
dren (white: 73%, black: 4%) aged 6 to <12 years with
PAR,26 which is consistent with the results in our
study. In addition, Máspero et al. reported that FFNS
55 μg showed significantly greater reduction in each
four individual nasal symptom scores, which is also
consistent with the results in our study. In our study,
three of the four nasal symptom scores: sneezing, rhi-
norrhea and nasal congestion, were evaluated based
on the Japanese guideline.1,2 The scoring of sneezing
and rhinorrhea in the Japanese guideline is based on
the frequencies of sneezing and nose-blowing, which
is different from the measures used in the study re-
FFNS in Japanese Children with PAR
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Fig.　2　Change in Rhinoscopic fi ndings (FAS). A, Swelling of inferior turbinate mucosa. 
B, Quantity of nasal discharge. P-value: Comparison of score change from baseline in in-
dividual subjects (FFNS 55 μg vs. Placebo, Wilcoxon’s 2-sample test). No adjustments for 
multiplicity. FFNS, fl uticasone furoate nasal spray; FAS, full analysis set.
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Table　4　Mean change from baseline in TOSS (sub-group analysis in FAS: baseline TOSS > 0)
Placebo (N = 92) FFNS 55 μg (N = 99)
Baseline Mean (SD) 2.3 (1.78) 2.1 (1.62)
Entire treatment period LS mean change (SE) -0.47 (0.11) -0.77 (0.11)
LS mean difference† - -0.302
p-value vs. placebo - 0.056
Week 1 LS mean change (SE) -0.35 (0.11) -0.56 (0.11)
LS mean difference† - -0.207
p-value vs. placebo - 0.185
Week 2 LS mean change (SE) -0.56 (0.13)‡ -0.99 (0.13)
LS mean difference† - -0.428
p-value vs. placebo - 0.020
TOSS, total ocular symptom score; FAS, full analysis set; FFNS, fl uticasone furoate nasal spray; LS, least square.
†LS mean difference = LS mean change in FFNS 55 μg minus LS mean change in placebo.
‡n = 90.
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Table　5　Adverse events with ≥2% incidence during the treatment and follow-up periods (SP)
Number of patients (%)
Placebo (N = 130) FFNS 55 μg (N = 131)
Nasopharyngitis 3 (2%) 6 (5%)
Epistaxis 3 (2%) 2 (2%)
Alanine aminotransferase increased 2 (2%) 0
Aspartate aminotransferase increased 2 (2%) 0
Conjunctivitis allergic 0 2 (2%)
Headache 2 (2%) 0
SP, safety population; FFNS, fl uticasone furoate nasal spray.
ported by Máspero et al.. In the previous reports in-
cluding Máspero’s, nasal symptom scores were evalu-
ated based on the guidance for industry on allergic
rhinitis issued by the Food and Drug Administration
(FDA). Consistent results with different measuring
systems strengthen evidence for the efficacy of
FFNS.
Rhinoscopy scores are investigator-rated objective
nasal symptoms scores, providing additional informa-
tion to the parentguardianpatient-rated subjective
score. This is the first study assessing efficacy of
FFNS using rhinoscopy scores in children with AR,
and shows a significant reduction in rhinoscopy
scores of mucosal swelling and nasal discharge com-
pared with placebo. These objective findings, which
are consistent with the results of parentguardian
patient-rated subjective scores, further support the ef-
ficacy of FFNS.
Studies in adults and adolescents have shown the
efficacy of INS in improving ocular symptoms associ-
ated with AR,18,20,21 and several mechanisms of action
have been proposed to explain the effects of INS on
these symptoms, including improvements due to
modulation of the naso-ocular reflex.27 In children,
however, few studies have examined the efficacy of
INS on ocular symptoms associated with AR, espe-
cially in PAR.28-30 Here we report that, in a subgroup
analysis in Japanese children with PAR with a base-
line TOSS > 0, TOSS was reduced significantly in the
FFNS 55 μg group compared with placebo in the sec-
ond week and reduced numerically but not signifi-
cantly in the first week. One of the reasons for non-
significance in the first week might be the smaller
numbers in the evaluated population. To our knowl-
edge, however, this is the first study that shows the
efficacy of INS in improving ocular symptoms in chil-
dren with PAR compared with placebo. Further study
is needed to confirm the efficacy of INS on ocular
symptoms in children with AR.
The safety findings of this study show that FFNS
55 μg, once daily were well tolerated in Japanese chil-
dren aged 6 to <15 years, with the incidence of ad-
verse events observed being similar to that of pla-
cebo. Safety results in this study are consistent with
previous reports in non-Japanese children where
FFNS 55 and 110 μg were reported to be well toler-
ated.26,31 Máspero et al. reported that adverse events
reported were of similar type and frequency between
FFNS 55 μg and placebo groups (FFNS 55 μg: 56%,
placebo: 59%) in non-Japanese children aged 2 to <12
years with PAR.26 Common adverse events observed
include pharyngolaryngeal pain, epistaxis, and
pyrexia. Common drug-related adverse event ob-
served was epistaxis.
Limitations of this study include the treatment pe-
riod of two weeks which may be too short to evaluate
the safety of FFNS in real-life settings. Safety in
longer term-use was assessed in a 12-weeks study of
FFNS 55 μg in Japanese children aged 2 to <15 years
with PAR, which is reported elsewhere. (ClinicalTri-
als.gov Identifier: NCT01622231, GlaxoSmithKline
protocol number: FFR116365.) Another limitation is
that the baseline TOSS value was not included as an
inclusion criterion and some participants in the study
had no ocular symptoms at baseline.
In conclusion, the results in this randomized,
placebo-controlled study suggested that FFNS 55 μg,
once daily was effective and tolerable for the treat-
ment of PAR in Japanese children aged 6 to <15
years.
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